Entry Inhibitors in Development

Tobira Therapeutics Initiates Phase 2b Trial of Cenicriviroc (July 5, 2011)
From Test Positive Aware Network
Fusion and Attachment Inhibitors (April 4, 2011)
To read PDF, click here.
From AIDS InfoNet
Cenicriviroc for Inflammation and HIV (October 25, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
Study Closes Vicriviroc Story (September 15, 2010)
From MedPage Today
TBR-652 Inhibits HIV, May Reduce Inflammation (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
An Anti-Inflammatory Antiretroviral? CCR5/CCR2 Antagonist TBR-652 Monotherapy Study Results: A Blog Entry by Myles Helfand (July 19, 2010)
In The XVIII International AIDS Conference, from TheBodyPRO.com
TBR-652: A CCR5 Antagonist -- With Anti-Inflammatory Properties? (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Anatomy of a Failure: Vicriviroc (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Vicriviroc Faces Further Challenges (Winter/Spring 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
New CCR5 Antagonist TBR-652 Shows Good Antiviral Activity in Early Study (February 18, 2010)
From aidsmap.com
CCR5 Antagonist Vicriviroc Fails to Surpass Potent Background Regimen (February 18, 2010)
From aidsmap.com
Why Vicriviroc Failed in Its Phase 3 Trials -- and What It May Mean for Future Studies in HIV Treatment-Experienced People (Feb. 17, 2010; 11:36 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Vicriviroc Fails for the Treatment Experienced (February 2010)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
ICAAC Update (January/February 2010)
Three new drugs in development, plus Isentress with Reyataz.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC
Incyte Halts Development of Promising New CCR5 Drug (April 10, 2008)
From Project Inform
CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc (February 3, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Schering-Plough Launches Phase III Trials of Experimental Antiretroviral Vicriviroc (September 19, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
CCR5 Entry Inhibitors: Vicriviroc (July 25, 2007)
Edwin DeJesus takes a look at recent data on vicriviroc, a CCR5 entry inhibitor currently being studied in treatment-experienced patients.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
Tests on HIV Drug Bring Good Results (May 4, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy (December 19, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
No Difference in HAART Response in Patients With X4-Using HIV (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Aplaviroc's Potency Against HIV Is Linked to Its Slow Dissociation From the CCR5 Receptor (August 17, 2006)
In XVI International AIDS Conference
Co-Receptor Conundrum: The Challenges of Turning Theory Into Reality (April 2006)
At the moment, there are many more questions than answers about an investigational class of drugs known as co-receptor inhibitors.
To read PDF, click here.
In TAGline, from Treatment Action Group
Entry Inhibitors: The Ups and Downs of Drug Development (Spring 2006)
AIDS activist Lynda Dee offers her take on the successes and failures of this new class of drugs.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
Entry Inhibitors in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From TheBody.com
Biotech Firm Creates Genetically Modified Immune Cells That Resist HIV Infection in Vitro (December 20, 2005)
[Archived Article]
Sangamo aims to modify patients' immune cells to possess a CCR5 receptor mutation that may make them "uninfectable".
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
University of Arkansas Scientists Win $10.2 Million Grant to Block HIV Receptor (December 8, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Entry Inhibitors: A Race to the Finish Line (November 2005)
[Archived Article]
A discussion on the risks and benefits of CCR5 blockers, and a report on the status of maraviroc, vicriviroc and aplaviroc.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
GlaxoSmithKline Stops All Clinical Trials of Entry Inhibitor Aplaviroc (October 25, 2005)
[Archived Article]
To read PDF, click here.
From GlaxoSmithKline
CCR5: A New Option for Those Who Have None Left (October 2005)
[Archived Article]
In Reasons for Hope, from Search for a Cure
Liver Toxicity Halts Trials of CCR5 Antagonist Aplaviroc in Treatment-Naive Patients (September 19, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
873140, a CCR5 Antagonist, Displays Activity Against R5-Tropic Virus in Naive and Experienced Patients (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Vicriviroc (SCH 417690, SCH-D), a CCR5 Antagonist, Generally Well Tolerated and Effective in 14-Day Monotherapy Study (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
The Antiviral Benefits of 873140, a CCR5 Antagonist (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
A New Era in HIV Treatment -- The Entry Inhibitors (January/February 2005)
[Archived Article]
Daniel S. Berger, M.D., reviews the concept behind the CCR5 inhibitor, a new type of entry inhibitor in development.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Entry Inhibitors: Hope on the Horizon? (October 2004)
[Archived Article]
A quick look at 10 entry inhibitors in early stages of development.
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
The X4 Files: CCR5 and CXCR4 Coreceptors (July/August 2004)
[Archived Article]
Several abstracts presented at AIDS 2004 examined these two sites on CD4 cells that may be targeted by a new class of antiretrovirals.
In GMHC Treatment Issues, from Gay Men's Health Crisis
On TheBodyPRO.com
Entry Inhibitors in Development (July 2004)
[Archived Article]
Brief updates on PRO 542, SCH-D, UK-427,857 and GW-873140.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
HIV Coreceptor Drugs on the Horizon (July/August 2004)
[Archived Article]
A summary of research on coreceptor inhibitors presented at AIDS 2004.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Drug Development News: CCR5 Blockers (May/June 2004)
[Archived Article]
Several are in clinical trials, but questions persist as to their usefulness in treatment-experienced patients.
In GMHC Treatment Issues, from Gay Men's Health Crisis
BMS 488043 (March/April 2004)
[Archived Article]
A review of the most recent studies regarding this attachment inhibitor in development that were presented at CROI 2004.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Receptor Blockers: GW873140, SCH-C, SCH-D (March/April 2004)
[Archived Article]
A quick look at data about these attachment inhibitors in development that was presented at CROI 2004.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
BMS-488043: New Mechanism to Stop HIV Entry (February 27, 2004)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
A Look at Antiretroviral Agents in Development -- An Attachment Inhibitor and Two CCR5 Receptor Antagonists (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
GW873140, a Promising CCR5 Inhibitor Candidate (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Waiting in the Wings: More New Drugs (November/December 2003)
[Archived Article]
A look at 908, TMC-125 and entry inhibitors in development.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Chinese Herb Blocks Chemokine Receptor, May Have Anti-HIV Effect (September 2003)
[Archived Article]
An abstract of a study on shikonin, a component of atraditional Chinese medicinal herb.
In Antimicrobial Agents and Chemotherapy
New Anti-HIV Therapies: Other Fusion Inhibitors (January 2003)
[Archived Article]
To read PDF, click here.
From Project Inform
Co-Receptor Overview: CC-CCR5 and CXCR4 (Fusin) (January 2003)
[Archived Article]
To read PDF, click here.
From Project Inform
On TheBodyPRO.com
Anti-HIV Candidates in the Pipeline: Entry and Integrase Inhibitors (Winter 2002/2003)
[Archived Article]
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
SCH-C Moves Ahead -- Carefully (September 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
Fusion Inhibitors (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Entry Inhibitors (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
New Targets Bring New Challenges (March 2002)
[Archived Article]
A closer look at integrase and entry inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Identification and Characterization of a Novel Inhibitor of HIV-1 Entry (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
The Next Target in Therapy: Viral Entry (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Development of CCR5 Antagonists as a New Class of Anti-HIV Therapeutic (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Entry and Integrase Inhibitors: The Next Class of Drugs (January 2001)
[Archived Article]
From AIDS Community Research Initiative of America
A New Type of Anti-HIV Drugs: Fusion Inhibitors (Spring 2000)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
Entry Inhibitors Are Featured at the 7th Conference on Retroviruses and Opportunistic Infections (Spring 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Simply Medical -- A Look at Fusion Inhibitors (November 1999)
[Archived Article]
In Body Positive, from Body Positive
Fusion and Fusion Inhibitors -- Understanding the News (Spring 1998)
[Archived Article]
In Women Alive Newsletter, from Women Alive